Q-omics provides the consensus-scored POLR3K profile across patient tissues and cancer cell-line models. POLR3K expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POLR3K is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, POLR3K RNA expression shows 18,223 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where POLR3K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3K survival associations across molecular data types. POLR3K RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3K RNA expression–survival associations across cancer types. High POLR3K expression shows unfavorable associations in UVM, UCS, LIHC, ESCA and LAML, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POLR3K RNA expression.
This table summarizes POLR3K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for POLR3K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3K shows higher tumor expression in COAD, STAD, LIHC, HNSC, BRCA and KIRP. The COAD box plot shows higher POLR3K RNA expression in tumor versus normal tissue (log2 FC = +1.698, t-test p < 0.001).
This table shows molecular features associated with POLR3K in patient tissues and cancer cell lines. In patient samples, POLR3K shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
